Why the study?
Although symptomatic severe aortic regurgitation is a Class I recommendation for surgical aortic valve replacement, practice patterns and drivers of receiving treatment remained to be evaluated.
Does surgical aortic valve replacement and management by high-SAVR-rate cardiologists improve 1-year mortality in patients with symptomatic severe aortic regurgitation?
Does surgical aortic valve replacement and management by high-SAVR-rate cardiologists improve 1-year mortality in patients with symptomatic severe aortic regurgitation?
Significant disparities exist in the treatment of symptomatic severe aortic regurgitation, with women and older patients less likely to receive SAVR, while management by cardiologists with higher SAVR rates is associated with improved 1-year survival.
These care gaps were associated with excess mortality in ssAR; leaves open whether cardiologist education can close them.
Background Symptomatic severe aortic regurgitation (ssAR) is a Class I recommendation for surgical aortic valve replacement (SAVR). We sought to evaluate the practice patterns and drivers of ssAR patients receiving SAVR treatment. Methods Using a US dataset of de-identified electronic health records, we identified integrated delivery network patients diagnosed with ssAR between 2008 and 2016 with ≥2 symptom-related notes (heart failure, angina, dyspnea, pre-syncope, or syncope) within six months prior to diagnosis. Results From a final cohort of 4,608 ssAR patients, 25.7% of ssAR patients underwent SAVR within 1 year of diagnosis; mortality at 1 year was 9% after SAVR, and 24% for those untreated. Using multilevel, multivariable, cause-specific models, women and patients >80 years old were found to be treated significantly less likely [hazard ratios (HR) 0.79 (95% confidence interval [CI]: 0.69–0.90) and 0.28 (0.22–0.37), respectively]. Patients with concomitant moderate/severe aortic stenosis [1.70 (1.43–2.03)], bicuspid aortic valve disease [1.33 (1.13–1.56)], and endocarditis [2.70 (1.04–3.57)] were more likely to be treated. Using multivariable Cox proportional hazard models, ssAR patients managed by cardiologists in the highest SAVR treatment rate tertile had a 23% lower risk of 1-year mortality compared to patients managed by cardiologists in the lowest SAVR treatment rate tertile [0.77 (0.60–0.98)]. Conclusions We identified significant disparities in the treatment of ssAR patients, specifically women, older patients, and patients managed by cardiologists with a lower SAVR treatment rate. These gaps should be addressed to level the quality of care delivered to all ssAR patients.
No takes yet. Share an insight, caveat, or question.
Thourani et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: